Skyrizi Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034

February 06, 2025 10:49 PM IST | By EIN Presswire
 Skyrizi Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, February 6, 2025 /EINPresswire.com/ -- What Are The Key Findings on the Historic Growth Rate of Skyrizi Market?

The Skyrizi market has witnessed substantial growth in recent years, growing from $XX million in 2024 to $XX million in 2025, showing a compound annual growth rate CAGR of XX%. The growth during the historic period can primarily be attributed to a rise in awareness of chronic inflammatory conditions, an increase in biosimilars, expansion in global healthcare access, expansion of clinical indications, and the strengthening of long-term safety data.

What are the Forecasted Trends for Skyrizi Global Market?

The forecast period paints a promising picture for the Skyrizi market, which is expected to see a rise of XX FCAGR in the next few years. The market, valued at $XX million in 2024, is projected to grow to $XX million in 2029 with an impressive compound annual growth rate CAGR of XX%. The expansion in the forecast period can be largely credited to growing adoption in psoriasis treatment, increasing patient numbers, a growing geriatric population, increasing awareness, improved diagnosis, and increased consumption of processed foods. Technological innovations in biologics, a shift towards combination therapies, advancements in diagnostic technologies, a trend from oral to injectable treatments, and artificial intelligence for drug development are likely to be major trends.

Get Your Free Sample Market Report: https://www.thebusinessresearchcompany.com/report/skyrizi-global-market-report

How Does the Rising Prevalence of Psoriasis Impact the Skyrizi Market Growth?

Fueling the growth of the Skyrizi market is the rising prevalence of psoriasis, a chronic autoimmune condition causing a rapid buildup of skin cells, resulting in scaling on the skin surface. Factors such as genetic predisposition, environmental triggers, increasing awareness, improved diagnosis rates, lifestyle modifications, and the growing impact of stress and immune-related disorders on overall health attribute to the increasing prevalence of psoriasis. Innovatively, Skyrizi, a biologic therapy targets interleukin-23 IL-23, strategically blocking the cytokine that plays a key role in the inflammatory process, reducing skin inflammation, easing symptoms like redness and scaling, and enhancing overall skin clearance in patients with moderate to severe plaque psoriasis.

What Are The Major Industry Players in The Skyrizi Global Market?

AbbVie Inc. is a significant industry player operating in the Skyrizi market. Their prominence in the market space is attributed to their strategic moves and advancements in the field.

What are the Emerging Trends in The Skyrizi Global Market?

Significant trends emerging in the Skyrizi Market include expanding therapeutic indications such as ulcerative colitis to enhance treatment outcomes for autoimmune diseases. For instance, Skyrizi, approved for treating moderate-to-severe ulcerative colitis UC, shows substantial clinical improvements in patients who have not responded to other treatments.

The Skyrizi Global Market Segmentation:

Segments in this market include:
1 By Indication: Plaque Psoriasis; Crohn's Disease; Ulcerative Colitis
2 By Formulation: Pre-Filled Syringes; Vials
3 By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Regional Insights: North America Dominates the Skyrizi Market

In 2024, North America emerged as the largest region in the Skyrizi market and is expected to continue being the fastest-growing region in the forecast period. Other regions covered in this market report include Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Order Your Report Now For A Swift Delivery: https://www.thebusinessresearchcompany.com/sample.aspx?id=20266&type=smp

Browse for more similar reports-
Ocular Inflammation Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/ocular-inflammation-treatment-global-market-report
Anti-Inflammatory Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report
Inflammatory Bowel Disease Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Explore more such reports from The Business Research Company. With over 15000+ reports across 27 industries covering 60+ geographies, The Business Research Company is renowned for delivering comprehensive, data-rich research and insights. With access to 1,500,000 datasets, in-depth secondary research, and unique insights from industry leaders, your business can stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.